News of Note—Enteromedics rebrands as ReShape LifeSciences, and more

A pile of newspapers

> Following its $38 million acquisition of ReShape Medical earlier this month, Enteromedics is rebranding as ReShape Lifesciences. MassDevice article

> Medtronic unveiled the first economic analysis of professional continuous glucose monitoring in people with Type 2 diabetes. The study, which analyzed data from more than 5,600 people who had used professional CGM in the U.S., showed “significant cost avoidance” when the system was used during a therapy change or at least twice a year. Abstract

> When Animas announced it would exit the insulin pump business in the U.S., it tapped Medtronic to transfer its customers to new devices. Insulet and partners Tandem and Dexcom have since offered welcome programs for Animas users. Now, Tandem is extending its offer period from Dec. 31 to March 31, 2018. Release | Read more about Insulet


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Suggested Articles

Thermo Fisher Scientific has begun early talks to take over Dutch diagnostics maker Qiagen, according to reports.

Atomwise and Velocity Pharmaceutical Development co-founded a company to carry AI-derived drugs through preclinical testing and into takeout deals.

Sera Prognostics has raised $36 million in funding to help commercialize its blood test for assessing the risk of premature births.